**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 60251

**Manuscript Type:** ORIGINAL ARTICLE

***Prospective Study***

**Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study**

Makker J *et al.* Elastography in type 2 diabetes

Jasbir Makker, Hassan Tariq, Kishore Kumar, Madhavi Ravi, Danial Haris Shaikh, Vivien Leung, Umar Hayat, Muhammad T Hassan, Harish Patel, Suresh Nayudu, Sridhar Chilimuri

**Jasbir Makker, Hassan Tariq, Kishore Kumar, Madhavi Ravi, Danial Haris Shaikh, Vivien Leung, Harish Patel, Suresh Nayudu, Sridhar Chilimuri,** Division of Gastroenterology, Department of Medicine, BronxCare Health System, Bronx, NY 10457, United States

**Umar Hayat,** KU School of Medicine-Wichita, University of Kansas, Wichita, KS 67214, United States

**Muhammad T Hassan,** Department of Medicine, BronxCare Health System, Bronx, NY 10457, United States

**Author contributions:** Makker J and Tariq H designed and performed the study, analyzed the data, and drafted the manuscript; Kumar K and Ravi M collected the clinical data and performed Liver elastography; Hayat U and Patel H performed the bio statistical analysis; Shaikh DH, Hassan MT, Patel H and Leung V made critical revisions to the manuscript; Nayudu S and Chilimuri S supervised the study performance, reviewed the manuscript and gave final approval of the version of the article to be published.

**Corresponding author: Jasbir Makker, MBBS, Attending Doctor,** Division of Gastroenterology, Department of Medicine, BronxCare Health System, 1650 Selwyn Avenue, Apt 10C, Bronx, NY 10457, United States. jmakker@bronxcare.org

**Received:** November 7, 2020

**Revised:** December 12, 2020

**Accepted:** December 27, 2020

**Published online:** February 14, 2021

**Abstract**

BACKGROUND

Nonalcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM) have an intricate bidirectional relationship. Individuals with T2DM, not only have a higher prevalence of non-alcoholic steatosis, but also carry a higher risk of progression to nonalcoholic steatohepatitis. Experts still differ in their recommendations of screening for NAFLD among patients with T2DM.

AIM

To study the prevalence of NAFLD and advanced fibrosis among our patient population with T2DM.

METHODS

During the study period (November 2018 to January 2020), 59 adult patients with T2DM and 26 non-diabetic control group individuals were recruited prospectively. Patients with known significant liver disease and alcohol use were excluded. Demographic data and lab parameters were recorded. Liver elastography was performed in all patients.

RESULTS

In the study group comprised of patients with T2DM and normal alanine aminotransferase levels (mean 17.8 ± 7 U/L), 81% had hepatic steatosis as diagnosed by elastography. Advanced hepatic fibrosis (stage F3 or F4) was present in 12% of patients with T2DM as compared to none in the control group. Patients with T2DM also had higher number of individuals with grade 3 steatosis [45.8% *vs* 11.5%, (*P* < 0.00001) and metabolic syndrome (84.7% *vs* 11.5%, *P* < 0.00001)].

CONCLUSION

A significant number of patients with T2DM, despite having normal transaminase levels, have NAFLD, grade 3 steatosis and advanced hepatic fibrosis as measured by liver elastography.

**Key Words:** Advanced liver fibrosis; Diabetes; Steatosis; Normal transaminases; Fatty liver disease; Metabolic syndrome

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Makker J, Tariq H, Kumar K, Ravi M, Shaikh DH, Leung V, Hayat U, Hassan MT, Patel H, Nayudu S, Chilimuri S. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. *World J Gastroenterol* 2021; 27(6): 523-533

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i6/523.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i6.523

**Core Tip:** Individuals with type 2 diabetes mellitus (T2DM) have a higher prevalence of non-alcoholic steatosis and a higher risk of progression to non-alcoholic steatohepatitis and cirrhosis. Experts differ in their screening recommendations for nonalcoholic fatty liver disease among patients with T2DM. We prospectively recruited and performed liver elastography on 59 diabetics and 26 non-diabetic control patients. Patients with known liver disease and alcohol use were excluded. Our study shows advanced fibrosis is prevalent among patients with T2DM as compared to non-diabetics, even with normal liver enzymes. Screening for liver fibrosis in all patients with T2DM should be considered, regardless of liver enzyme levels.

**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of clinico-pathological conditions ranging from simple fatty liver disease to nonalcoholic steatohepatitis (NASH). The risk of progression of NASH to cirrhosis has previously been estimated at 21%-26% over a mean follow up of 8.2 years[1]. With the globalization of western diets and increasingly sedentary lifestyles, obesity rates have skyrocketed to epidemic proportions. In parallel with obesity, the prevalence of NAFLD has dramatically increased. The prevalence of NAFLD worldwide ranges from 6% to 35% depending on the method used for diagnosis and the study population[2]. The prevalence in United States has ranged between 11%-34% with the most recent study reporting a prevalence of 46%[3]. As a result of its increasing prevalence, NAFLD has now become the leading cause of liver disease in the western countries[2]. With the rising rates of NAFLD, and the availability of effective durable treatment options for other chronic liver diseases like chronic hepatitis C, experts have predicted NAFLD to become the leading cause of liver transplantation in the near future.

NAFLD and type-2 diabetes mellitus (T2DM) are intricately related to each other and this relationship is bidirectional. Development of insulin resistance is a key phenomenon underlying NAFLD as well as T2DM and as a result, these two disorders commonly occur together. Individuals with T2DM have a higher prevalence of NAFLD[4]. Individuals with T2DM who develop non-alcoholic steatosis also carry a higher risk of progression to NASH[5]. Development of NASH is characterized by progressive hepatocyte necroinflammation which is an important harbinger of cirrhosis and its associated complications such as hepatocellular cancer. In a study from the United States. Involving 1249 patients with T2DM and biopsy proven NAFLD, prevalence of NASH and advanced liver fibrosis was 69.2% and 41% respectively[6]. A Canadian study with a 12-year follow-up involving nearly 2.5 million participants, among which nearly one-fifth had newly diagnosed T2DM, found more than two-fold risk of incident liver cirrhosis in patients with newly diagnosed T2DM[7].

Despite the alarming rise in NAFLD prevalence among patients with T2DM, major societies differ in their recommendations about screening for NAFLD among patients with T2DM. The American Association for the Study of Liver Diseases does not recommend NAFLD screening in individuals with T2DM due to its unknown long-term benefits and cost-effectiveness[8]. On the other hand, American Diabetes Association recommends assessment of liver fibrosis in patients with T2DM and elevated transaminases[9]. Our study was conducted to explore the prevalence of NAFLD and advanced fibrosis among our minority inner city population with T2DM who had normal transaminases.

**MATERIALS AND METHODS**

***Study group***

From November 2018 to January 2020, all patients aged 18 years and above with T2DM attending the endocrine clinic at our hospital were offered enrollment in this prospective cohort study. All patients who agreed, provided a written and informed consent for their participation. Patients with a known diagnosis of cirrhosis, chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, drug induced hepatitis, cholestatic liver disease, hemochromatosis and alcoholic liver disease were excluded. Patients with significant alcohol use defined as more than 20 g of daily alcohol use were excluded. Furthermore, any patient with alanine transaminase (ALT) level more than 40 (upper limit of normal at our lab) was excluded.

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in the Bronx Care Health System Institutional Review Board’s approval (IRB #05 10 18 04).

***Control group***

The control group comprised of patients without T2DM and normal ALT level (< 40 U/L) as defined by our lab. Patients were recruited from the gastroenterology clinic at our hospital. These patients had no known history of fatty liver disease. Exclusion criteria similar to the study group were applied.

***Clinical and laboratory parameters***

Demographic data including age, gender and ethnicity were collected. All comorbid medical conditions and a complete drug history were recorded *via* patient interviews. A physical examination including measurement of waist circumference, weight, height and body mass index (BMI) was performed at the time of inclusion. Laboratory data including liver enzymes, hemoglobin A1c, lipid profile available within one year of enrollment were recorded.

***Assessment of hepatic steatosis and fibrosis using transient elastography***

All patients were required to fast for three hours prior to elastography. Liver elastography was performed using the M or XL probe from Fibroscan 502 touch model (Echosens). The probe is automatically selected by the software based on thoracic perimeter and skin capsule distance measurements. Liver stiffness measurement and controlled attenuation parameter (CAP) which estimates the amount of liver fat was obtained. Elastography examination was considered reliable if at least 10 measurements were taken with an interquartile range interval per median LS less than 30%. Liver stiffness and CAP are calculated as a median over minimum 10 validated measurements and expressed in kilopascals (Kpa) and decibel per meter (db/m), respectively. Cut off for stage F0-1, F2, F3 and F4 fibrosis were ≤ 7 Kpa, ≥ 7.5 Kpa, ≥ 10 Kpa and ≥ 14.0 Kpa, respectively[10]. Cut off for CAP to diagnose hepatic steatosis grade 1 (5%-33% steatosis), grade 2 (34%-66% steatosis) and grade 3 (> 66% steatosis) were 238 db/m, 259 db/m and 290 db/m respectively[11].

***Metabolic syndrome***

Metabolic syndrome was defined by the National Cholesterol Education Program’s Adult Treatment Panel III criteria. It is defined as presence of at least three of the following criteria: waist circumference > 102 cm in men or > 88 cm in women, plasma triglycerides ≥ 150 mg/dL, high density lipoprotein cholesterol < 40 mg/dL in men or < 50 mg/dL in women, blood pressure ≥ 130/85 mmHg, and fasting plasma glucose ≥ 110 mg/dL[12].

***Sample size and statistical analysis***

Sample size estimation was based on the assumption that prevalence of advanced fibrosis among patients with T2DM is around 20%. For a power of 80% at 5% significance level, 57 patients were required in the study group.

Statistical analysis was performed using statistical analysis system statistical software, version 9.4 and Graphpad Prism software version 8.4.3. Frequencies and percentages were reported for categorical variables. Mean and standard deviations were reported for numerical continuous variables. Dichotomous variables were compared by Chi-square analysis using the Pearson test. A two-tailed value of < 0.05 was considered statistically significant. Bivariate analysis was done using analysis of variance to determine predictors of advanced fibrosis.

**RESULTS**

The study group comprised of 59 patients, whereas the control group had 26 patients. Demographics and baseline characteristics of both the groups were compared as shown in Table 1. The mean duration of T2DM in the study group was 15 ± 9 years. Diabetic microvascular complications including retinopathy, nephropathy, and neuropathy were prevalent in 22%, 30% and 17% of study patients, respectively. 41% of these patients were on insulin, 59% on metformin, 17% on sulfonylureas, 20% on glucagon-like peptide 1 receptor agonists, 8% on pioglitazone, 12% on sodium-glucose cotransporter-2 inhibitors, and 19% on dipeptidyl peptidase 4 inhibitors. Mean BMI of patients in the study group was significantly higher as compared to those in the control group (33.1 ± 8.4 *vs* 27.6 ± 4.7, *P =* 0.0002). A total of 7 patients in the study group were not obese and had BMI < 25, 18 patients were with BMI: 25-29.9, 11 had a BMI: 30-34.9, 14 had a BMI: 35-39.9, and 9 patients had a BMI of > 40.

***Prevalence of hepatic fibrosis***

Elastography revealed that 76% of our study group patients had absent or low-grade (F0-1) fibrosis, 12% had F2 stage fibrosis, 5% had F3 stage fibrosis, and 7% had F4 stage fibrosis. Advanced fibrosis stage (F3 or F4) was diagnosed in a total of seven (12%) patients from the study group (Figure 1). In the control group none of the patients had advanced stage fibrosis, 2 (8%) patients had F2 fibrosis and 24 (92%) patients had F0-1 stage fibrosis (Figure 2).

***Prevalence of hepatic steatosis***

Eighty-one percent of our study group patients with T2DM had hepatic steatosis as diagnosed by liver elastography. Steatosis grade 3 was prevalent in 27 (46%) patients as compared to 3 (12%) patients in the control group (*P* value < 0.00001). Steatosis stage 0, 1, and 2 were diagnosed in 11 (19%), 8 (13%), and 13 (22%) patients respectively in the study group (Figure 3). In comparison, the control group had 11 (42%), 7 (27%), and 5 (19%) patients with steatosis stage 0, 1, and 2 respectively.

***Prevalence of metabolic syndrome***

Metabolic syndrome was more prevalent among the study group patients. Fifty (85%) patients were diagnosed with metabolic syndrome in the study group and on the contrary only three (12%) patients in the control group had metabolic syndrome (*P* < 0.00001). Among the 27 (46%) patients in the study group who had S3 steatosis, 26 (96%) had metabolic syndrome. Twenty-eight out of the 59 (48%) patients who had metabolic syndrome in the study group met three criteria for metabolic syndrome, 13 (22%) patients met four criteria and remaining 9 (15%) patients met all the five criteria for metabolic syndrome (Figure 4).

Bivariate Analysis was performed using analysis of variance to determine predictors of advanced fibrosis. Duration of T2DM was found to be a significant predictor (*P* < 0.05) of advanced fibrosis. Age (*P =* 0.29), BMI (*P =* 0.30), and waist circumference (*P =* 0.46) had no association with advanced fibrosis.

**DISCUSSION**

With the prevalence rate of obesity and T2DM reaching epidemic proportions, NAFLD has become a health crisis. NAFLD is seen frequently in T2DM with prevalence reported as high as 74% reported in one of the studies[13]. The pathophysiology of NAFLD and T2DM are intricately intertwined with insulin resistance serving as the common mediator. Severe hepatic necro-inflammation can progress to cirrhosis, especially more so in patients with T2DM. A study conducted by McPherson[14] has previously shown an alarmingly high rate of fibrosis progression not only in patients with NASH but also in individuals with NAFLD. The same study also showed that 22% of their patients who had NAFLD at their index liver biopsy showed progression to advanced fibrosis on their follow-up biopsy. Co-occurrence of NAFLD and T2DM poses a heightened risk of extrahepatic morbidity and mortality from cardiovascular disease, chronic kidney disease and hepatocellular cancer[15]. Despite these findings, guidelines from the expert societies differ in their opinion regarding the utility of screening for hepatic fibrosis in patients with NAFLD.

The prevalence of NAFLD in our study patients was higher than in previous reports, ranging from 40% to 70% in patients with T2DM[16]. Eighty-one percent of our patients with T2DM were found to have hepatic steatosis and nearly half of them had S3 steatosis. The prevalence of NAFLD in patients with T2DM previously reported in literature varies depending on the ethnicity and method used to diagnose NAFLD. Hispanics have been reported to have highest prevalence of non-alcoholic fatty liver disease[13] and more than 80% of our study patients were of Hispanic ethnicity.

Our study demonstrated that even patients with T2DM who had normal ALT levels were at risk of severe progressive liver disease. Twelve percent of our patients with T2DM had undiagnosed advanced fibrosis. Importantly, these patients who were noted to have advanced fibrosis had normal transaminases (mean ALT = 17.8 ± 7 U/L). Thus, based on current guidelines, these patients without clinically obvious cirrhosis would have gone undiagnosed for years. Among the seven study patients with BMI less than 25, five patients met criteria for metabolic syndrome, four patients had hepatic steatosis and one patient had advanced stage hepatic fibrosis. Thus, even non-obese patients with T2DM and normal transaminases could not be assumed to have a safer metabolic profile.

A cross sectional study done by Tuong *et al*[17] similarly studied the prevalence of hepatic fibrosis among patients with T2DM and found 73.3% of their diabetic patients to have NAFLD. The prevalence of F3 and F4 in their study group was 5.9% and 3.6% respectively, but they included patients with elevated transaminases as well, with a mean ALT of 60.6 U/L in the advanced fibrosis group. Another cross-sectional study by Lai *et al*[18] using transient elastography in patients with T2DM, showed a prevalence of cirrhosis and advanced fibrosis in 13.5% and 21% of patients, respectively. This study also included patients with elevated transaminases with a mean ALT of 38 U/L in patients with cirrhosis. A Turkish study found prevalence of advanced fibrosis of 16.9% and cirrhosis of 8% in their patients with T2DM. The mean ALT in their patients with F3 fibrosis was 39 U/L[19]. In a large prospective cohort study from Hong Kong involving 1918 patients with T2DM, increased liver stiffness suggestive of F3 or F4 fibrosis was found in 18.8% of their diabetic patients with normal ALT, defined as ALT less than 30 U/L in men and less than 19 U/L in women. This data is predominantly from an Asian population and does not reflect our study population[20]. In a study from Australia, prevalence of significant fibrosis, defined by the study as stage F2 and above, was 35% in diabetics. The mean ALT level was 38 U/L among these patients with significant fibrosis[21]. In a prospective French study, significant fibrosis defined as liver stiffness > 8.7 kPa was found in 12.9% of patients with T2DM. However, this study did not exclude patients with significant alcohol use and some of their patients found to have cirrhosis reported > 70 drinks of alcohol per week[22]. Prevalence of F4 stage fibrosis defined as liver stiffness > 9.5 kPA in another study from Romania was 18.6%. However, like most of the other studies, they too included patients with elevated ALT, with a significant number of patients having an ALT more than 40 U/L[23]. Currently, it is not the standard of care to assess liver fibrosis using liver biopsy in patients with normal ALT levels. However, it has been shown before that ALT is not a reliable criterion to exclude patients for assessment of liver fibrosis[24]. In this Italian study involving 458 Liver biopsy confirmed NAFLD patients, 63 patients had normal ALT. NASH was demonstrated in 27% of those who had ALT levels less than 30 U/L in men and 19 U/L in women.

Liver biopsy is considered a gold standard diagnostic method for evaluating chronic liver diseases. In patients with NAFLD, it is particularly useful to assess for the presence of steatohepatitis which may progress to the development of cirrhosis. However, liver biopsy is an imperfect tool that is costly and invasive. It is associated with complications including pain in up to 50% of patients, serious bleeding in 0.6%, injury to other internal organs in about 0.08% and rarely death in 0.1% of patients[25]. Considering the enormous burden of NAFLD in our communities and the invasive nature of liver biopsy, it is not practically feasible to subject all patients with NAFLD to liver biopsy. Surrogate non-invasive methods of liver fibrosis assessment have been developed and are widely available. Vibration controlled liver elastography is one such tool, that is commonly available in United States. It is a quick office-based procedure with acceptable intra-observer and inter-observer variability which has been validated worldwide[26].

We noticed striking gender differences in our study population. In general, higher prevalence of NAFLD has been reported in males as compared to female patients. However, when age specific gender differences are explored further, post-menopausal women have a higher prevalence of NAFLD as compared to men[27]. Our study results are consistent with these findings, demonstrating that 86% of all female patients as compared to 78% of all male patients had NAFLD. Among the 23 male patients in the study group (mean age of 63 years) only one (4%) patient had advanced fibrosis. In comparison, 36 patients were females (mean age of 62 years) and a total of six (17%) had advanced fibrosis. Female patients not only had higher prevalence of NAFLD, but also had a higher prevalence of grade 3 steatosis which was observed in 55% of females as compared to 30% of males. Although gender has been consistently shown to be a significant modifier, gender specific personalized therapy for NAFLD has not been explored and further research is needed to investigate this area.

***Clinical implication***

Considering the high prevalence of T2DM and NAFLD in our modern world, the burden of undiagnosed cirrhosis is enormous. Diagnosing these patients in a timely fashion would provide the opportunity to adopt intensive lifestyle modifications, and consequently avoid or at the least delay the progression to advanced hepatic fibrosis. Thus, it is important to recognize these patients early on, emphasize the progression of untreated NAFLD to liver cirrhosis, and potentially reduce morbidity, mortality and its related health care burden.

***Study limitations***

Our study has several limitations. Firstly, the number of overall patients in our study group is small and hence further studies with larger sample sizes are needed to validate our results. Second, we utilized liver elastography to diagnose NAFLD and liver biopsy was not performed in our patients, hence, we do not know the prevalence of NASH, which is the main driver for cirrhosis. However, it is not only unethical but risky too, to perform a liver biopsy in all T2DM patients especially with normal transaminase levels. Thirdly, the inclusion criteria in our study required a normal ALT level, defined as less than 40 U/L by our lab, which is higher than the current accepted standard. Nevertheless, the mean ALT level in the control and study group was 17 and 17.8 U/L, respectively. Fourthly, patients in our study group are older than the control group. Multiple studies have explored the influence of age on liver stiffness, and the results have been conflicting so far, reporting no difference across age groups[28,29], higher liver stiffness measurement in younger[30] or older[31] age. Lastly, our study and control group populations comprised predominantly of Hispanics and African Americans and hence these results cannot be generalized.

**CONCLUSION**

In conclusion, our study data shows that significant liver disease is prevalent among patients with T2DM, even with normal ALT levels. Measuring ALT levels in our study as a predictor of significant liver disease was unreliable. Timely work up with non-invasive techniques for estimation of liver fibrosis is warranted to prevent presentation at advanced stages of fibrosis. Primary care physicians and endocrinologists should be aware of this complication and should consider screening for liver fibrosis in all patients with T2DM, regardless of liver enzyme levels. Larger studies involving other ethnic groups are needed to validate our results.

**ARTICLE HIGHLIGHTS**

***Research background***

With the current obesity epidemic, prevalence of non-alcoholic fatty liver disease (NAFLD) has increased. Individuals with type 2 diabetes mellitus (T2DM) have a higher prevalence of non-alcoholic steatosis, may carry a higher risk of progression to nonalcoholic steatohepatitis and eventually cirrhosis.

***Research motivation***

Experts still differ in their recommendations of screening for NAFLD among patients with T2DM.

***Research objectives***

To study the prevalence of NAFLD and advanced fibrosis among our patient population with T2DM with normal transaminases and without known liver disease.

***Research methods***

Prospective cohort study assessing hepatic steatosis and fibrosis using transient elastography in 59 patients with T2DM, compared to 26 non-diabetic control group patients.

***Research results***

In our study group, 81% of patients had hepatic steatosis and 12% had advanced fibrosis on liver elastography. In the control group none of the patients had advanced stage fibrosis. Grade 3 steatosis was prevalent in 46% of patients in the study group as compared to 12% patients in the control group (*P* value < 0.00001).

***Research conclusions***

A significant number of patients with T2DM, despite having normal transaminase levels, have advanced fibrosis or steatosis as measured by liver elastography.

***Research perspectives***

Physicians should be aware of prevalence of significant liver disease among patients with T2DM, even with normal liver enzymes and should consider earlier screening to prevent presentation at advanced stages of fibrosis. Larger studies are needed to confirm and validate our results.

**REFERENCES**

1 **Matteoni CA**, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999; **116**: 1413-1419 [PMID: 10348825 DOI: 10.1016/s0016-5085(99)70506-8]

2 **Vernon G**, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]

3 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

4 **Williamson RM**, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetes Care* 2011; **34**: 1139-1144 [PMID: 21478462 DOI: 10.2337/dc10-2229]

5 **Bian H**, Zhu X, Xia M, Yan H, Chang X, Hu X, Pan B, Guo W, Li X, Gao X. Impact of Type 2 Diabetes on Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. *Endocr Pract* 2020; **26**: 444-453 [PMID: 31968197 DOI: 10.4158/EP-2019-0342]

6 **Bazick J**, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. *Diabetes Care* 2015; **38**: 1347-1355 [PMID: 25887357 DOI: 10.2337/dc14-1239]

7 **Porepa L**, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. *CMAJ* 2010; **182**: E526-E531 [PMID: 20566726 DOI: 10.1503/cmaj.092144]

8 **Chalasani N**, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018; **67**: 328-357 [PMID: 28714183 DOI: 10.1002/hep.29367]

9 **American Diabetes Association.** 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: *Standards of Medical Care in Diabetes-2020*. *Diabetes Care* 2020; **43**: S37-S47 [PMID: 31862747 DOI: 10.2337/dc20-S004]

10 **Bonder A**, Afdhal N. Utilization of FibroScan in clinical practice. *Curr Gastroenterol Rep* 2014; **16**: 372 [PMID: 24452634 DOI: 10.1007/s11894-014-0372-6]

11 **Wang Y**, Fan Q, Wang T, Wen J, Wang H, Zhang T. Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. *Int J Clin Exp Med* 2015; **8**: 17654-17663 [PMID: 26770355]

12 **Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.** Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486-2497 [PMID: 11368702 DOI: 10.1001/jama.285.19.2486]

13 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

14 **McPherson S**, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. *J Hepatol* 2015; **62**: 1148-1155 [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034]

15 **Byrne CD**, Targher G. NAFLD: a multisystem disease. *J Hepatol* 2015; **62**: S47-S64 [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012]

16 **Lazo M**, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. *Semin Liver Dis* 2008; **28**: 339-350 [PMID: 18956290 DOI: 10.1055/s-0028-1091978]

17 **Tuong TTK**, Tran DK, Phu PQT, Hong TND, Dinh TC, Chu DT. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. *Diagnostics (Basel)* 2020; **10**: [PMID: 32183383 DOI: 10.3390/diagnostics10030159]

18 **Lai LL**, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. *J Gastroenterol Hepatol* 2019; **34**: 1396-1403 [PMID: 30551263 DOI: 10.1111/jgh.14577]

19 **Demir M**, Deyneli O, Yılmaz Y. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. *Turk J Gastroenterol* 2019; **30**: 266-270 [PMID: 30411703 DOI: 10.5152/tjg.2018.18559]

20 **Kwok R**, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, Kong AP, Wong VW. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. *Gut* 2016; **65**: 1359-1368 [PMID: 25873639 DOI: 10.1136/gutjnl-2015-309265]

21 **Casey SP**, Kemp WW, McLean CA, Topliss DJ, Adams LA, Roberts SK. A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. *Scand J Gastroenterol* 2012; **47**: 836-841 [PMID: 22519948 DOI: 10.3109/00365521.2012.677955]

22 **de Lédinghen V**, Vergniol J, Gonzalez C, Foucher J, Maury E, Chemineau L, Villars S, Gin H, Rigalleau V. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes. *Dig Liver Dis* 2012; **44**: 413-418 [PMID: 22285146 DOI: 10.1016/j.dld.2011.12.005]

23 **Sima A**, Sporea I, Timar R, Vlad M, Braha A, Popescu A, Nistorescu S, Mare R, Sirli R, Albai A, Albai O, Diaconu L, Sorescu T, Popescu S, Sima L. Non-Invasive Assessment of Liver Steatosis and Fibrosis using Transient Elastography and Controlled Attenuation Parameter in Type 2 Diabetes Patients. *Acta Endocrinol (Buchar)* 2018; **14**: 394-400 [PMID: 31149289 DOI: 10.4183/aeb.2018.394]

24 **Fracanzani AL**, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *Hepatology* 2008; **48**: 792-798 [PMID: 18752331 DOI: 10.1002/hep.22429]

25 **Tapper EB**, Lok AS. Use of Liver Imaging and Biopsy in Clinical Practice. *N Engl J Med* 2017; **377**: 756-768 [PMID: 28834467 DOI: 10.1056/NEJMra1610570]

26 **Fraquelli M**, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut* 2007; **56**: 968-973 [PMID: 17255218 DOI: 10.1136/gut.2006.111302]

27 **Lonardo A**, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. *Hepatology* 2019; **70**: 1457-1469 [PMID: 30924946 DOI: 10.1002/hep.30626]

28 **Ling W**, Lu Q, Quan J, Ma L, Luo Y. Assessment of impact factors on shear wave based liver stiffness measurement. *Eur J Radiol* 2013; **82**: 335-341 [PMID: 23116805 DOI: 10.1016/j.ejrad.2012.10.004]

29 **Mulabecirovic A**, Mjelle AB, Gilja OH, Vesterhus M, Havre RF. Liver elasticity in healthy individuals by two novel shear-wave elastography systems-Comparison by age, gender, BMI and number of measurements. *PLoS One* 2018; **13**: e0203486 [PMID: 30216377 DOI: 10.1371/journal.pone.0203486]

30 **Colombo S**, Belloli L, Zaccanelli M, Badia E, Jamoletti C, Buonocore M, Del Poggio P. Normal liver stiffness and its determinants in healthy blood donors. *Dig Liver Dis* 2011; **43**: 231-236 [PMID: 20817625 DOI: 10.1016/j.dld.2010.07.008]

31 **Roulot D**, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, Le Clesiau H, Beaugrand M. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. *Gut* 2011; **60**: 977-984 [PMID: 21068129 DOI: 10.1136/gut.2010.221382]

**Footnotes**

**Institutional review board statement:** The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in the Bronx Care Health System Institutional Review Board’s approval (IRB #05 10 18 04).

**Informed consent statement:** All study participants provided written informed consent prior to study enrollment.

**Conflict-of-interest statement:** All authors report no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding Author's Membership in Professional Societies:** American College of Gastroenterology; American Society for Gastrointestinal Endoscopy; American Gastroenterological Association.

**Peer-review started:** November 7, 2020

**First decision:** December 3, 2020

**Article in press:** December 27, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Malnick SD, Zhang LL **S-Editor:** Zhang L **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**

**图表, 瀑布图

描述已自动生成**

**Figure 1 Comparison of S3 steatosis, F3/4 fibrosis and metabolic syndrome among control (non-diabetic) and study (diabetic) group.**

图表, 条形图

描述已自动生成

**Figure 2 Control and study group patients stratified according to fibrosis stage.**

图表, 条形图

描述已自动生成

**Figure 3 Control and study group patients stratified according to steatosis stage.**

图表, 条形图

描述已自动生成

**Figure 4 Control and study group patients stratified according to number of criteria met for metabolic syndrome.**

**Table 1 Comparison of characteristics between control and study group**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variate** | **Control group, *n* = 26** | **Study group, *n* = 59** | ***P* value** |
| Age (yr) | 53 ± 12.3 | 62 ± 11.7 | 0.0014 |
| Gender, *n* (%) |  |  | 0.8099 |
| Male | 9 (35) | 23 (39) |  |
| Female | 17 (65) | 36 (61) |  |
| Ethnicity, *n* (%) |  |  | 0.5005 |
| Hispanic | 21 (81) | 41 (69.5) |  |
| African American | 3 (12) | 13 (22) |  |
| Others | 2 (7) | 5 (8.5) |  |
| Waist circumference (cm) | 97.5 ± 8.4 | 98. 6 ± 18.5 | 0.7595 |
| BMI (kg/m2) | 27.6 ± 4.7 | 33.1 ± 8.4 | 0.0002 |
| Hypertension, *n* (%) | 15 (58) | 43 (73) | 0.2083 |
| Hyperlipidemia, *n* (%) | 10 (38) | 35 (59) | 0.0999 |
| ALT (U/L) | 17 ± 7 | 17.8 ± 7 | 0.7189 |
| Platelet count (109/L) | 258 ± 81 | 237 ± 61 | 0.2007 |
| Albumin (g/L) | 4.4 ± 0.3 | 4.3 ± 0.3 | 0.0687 |
| HDL (mg/dL) | 57.7 ± 18.2 | 49.7 ± 15.5 | 0.0588 |
| LDL (mg/dL) | 106.3 ± 33.6 | 87.4 ± 35.5 | 0.0231 |
| TG (mg/dL) | 122.5 ± 79.3 | 154.7 ± 77.9 | 0.0883 |
| HbA1c | 5.4 ± 0.3 | 7.9 ± 1.8 | < 0.0001 |
| Liver stiffness using elastography (kPa) | 5.2 ± 1.6 | 7.5 ± 9.6 | 0.2138 |
| CAP (dB/m) | 230 ± 70 | 284 ± 64 | 0.0008 |

BMI: Body mass index; ALT: Alanine transaminase; HbA1c: Hemoglobin A1c; CAP: Controlled attenuation parameter.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**